Fluvoxamine-d₄is intended for use as an internal standard for the quantification of fluvoxamine by GC- or LC-MS. Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI).¹It selectively inhibits reuptake of serotonin over norepinephrine reuptake in rat hypothalamic synaptosomes (K_is = 6.2 and 1,100 nM, respectively). Fluvoxamine (10 mg/kg) reduces immobility time in the forced swim test in mice, an effect that can be blocked by the sigma-1 (σ₁) receptor antagonist BD 1047 .²It also reduces marble-burying behavior in the marble-burying test in mice when administered at a dose of 45 mg/kg, indicating anxiolytic- or reduced obsessive compulsive-like behaviors.³Formulations containing fluvoxamine have been used in the treatment of obsessive compulsive disorder and social anxiety disorder.

1.Johnson, A.M.An overview of the animal pharmacology of paroxetineActa Psychiatr. Scand.80(Suppl. 350)14-20(1989) 2.Sugimoto, Y., Tagawa, N., Kobayashi, Y., et al.Involvement of the sigma1 receptor in the antidepressant-like effects of fluvoxamine in the forced swimming test in comparison with the effects elicited by paroxetineEur. J. Pharmacol.696(1-3)96-100(2012) 3.Hayashi, A., Yamashita, N., Baba, J., et al.Effects of co-administered fluvoxamine and diazepam, ethyl loflazepate or imipramine on marble-burying behavior in miceOyo Yakuri57(5-6)103-108(1999)